Alvotech is trading 3.14% up at ISK 722.00, with the immediate catalyst unclear. - No new company-specific announcement on September 24, 2026 clearly explains the move. - Recent positive sentiment followed the FDA’s favorable Reykjavik inspection classification and Barclays’ September 16 upgrade; both predate today’s session and are not confirmed as the direct cause. - Biotech is broadly weaker, so sector conditions do not explain Alvotech’s gain.